Seoul St. Mary's Hospital Analyzes Real-World Clinical Data from 62 Lecanemab-Treated Patients

It has been confirmed that the levels of immune proteins in the blood prior to antibody therapy in Alzheimer’s disease patients may be associated with the treatment’s efficacy as well as the potential risk of side effects.


On September 15, Seoul St. Mary's Hospital announced that the research team led by Professor Kang Dongwoo of the Memory Disorder Clinic in the Department of Psychiatry had analyzed the relationship between pre-treatment blood complement proteins C1q and C3 levels, and post-treatment amyloid reduction and occurrence of amyloid-related imaging abnormalities (ARIA).


From the left, Kang Dowoo and Professor Byun Kihwan at Seoul St. Mary's Hospital. Seoul St. Mary's Hospital

From the left, Kang Dowoo and Professor Byun Kihwan at Seoul St. Mary's Hospital. Seoul St. Mary's Hospital

View original image

The research team retrospectively analyzed real-world clinical data of 62 early-stage Alzheimer’s patients at Seoul St. Mary's Hospital who began treatment with lecanemab. Among these, the changes in amyloid burden were examined in 34 patients who underwent both pre-treatment and 26-week post-treatment amyloid positron emission tomography scans.


In the follow-up group, the mean centiloid value—representing brain amyloid burden—decreased from 67.8 before treatment to 38.1 after 26 weeks. The average reduction was 29.7 centiloids, accounting for 43.8% of the pre-treatment value.


The analysis indicated that higher pre-treatment C1q levels were associated with a smaller reduction in amyloid after 26 weeks. This trend remained consistent even after adjusting for age, gender, baseline amyloid burden, and the presence of apolipoprotein E ε4. In contrast, lower C3 levels were observed to be associated with a higher frequency of ARIA.


Out of the total 62 patients, ARIA occurred in 7 patients (11.3%): 5 had mild ARIA and 2 had moderate ARIA. The research team explained that C1q and C3 are part of the complement immune protein system, and that prior studies have suggested the complement pathway may be activated during the binding process between anti-amyloid antibodies and amyloid beta. This formed the basis for their current analysis.


The team stated that, should these results be replicated, C1q and C3 may serve as candidate biomarkers for pre-anti-amyloid antibody therapy risk assessment in addition to existing genetic information and brain imaging findings.



Professor Kang commented, “This study is significant in that we connected blood test data and brain imaging from actual clinical settings to confirm that complement proteins C1q and C3 may be associated with amyloid reduction and ARIA, respectively, in anti-amyloid antibody therapy.” He added, “We intend to verify the clinical utility of these findings through future multicenter studies.” The research results were published in the international journal 'Alzheimer’s & Dementia: Translational Research & Clinical Interventions.'


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing